Lilly Stops Testing of Schizophrenia Drug on Efficacy

Eli Lilly & Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.